Works by Ivy, S. Percy

Results: 41
    1
    2
    3

    Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer.

    Published in:
    Oncologist, 2019, v. 24, n. 9, p. 1149, doi. 10.1634/theoncologist.2019-0331
    By:
    • Heath, Elisabeth;
    • Heilbrun, Lance;
    • Mannuel, Heather;
    • Liu, Glenn;
    • Lara, Primo;
    • Monk, J. Paul;
    • Flaig, Thomas;
    • Zurita, Amado;
    • Mack, Philip;
    • Vaishampayan, Ulka;
    • Stella, Philip;
    • Smith, Daryn;
    • Bolton, Susan;
    • Hussain, Arif;
    • Al‐Janadi, Anas;
    • Silbiger, Daniel;
    • Usman, Muhammad;
    • Ivy, S. Percy
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 441, doi. 10.1007/s00280-008-0754-2
    By:
    • Krishnamurthi, Smitha S.;
    • Brell, Joanna M.;
    • Hoppel, Charles L.;
    • Egorin, Merrill J.;
    • Weaver, Karen C.;
    • Xiaolin Li;
    • Ingalls, Stephen;
    • Zuhowski, Eleanor T.;
    • Schluchter, Mark D.;
    • Dowlati, Afshin;
    • Cooney, Matthew M.;
    • Gibbons, Joseph;
    • Overmoyer, Beth A.;
    • Ivy, S. Percy;
    • Remick, Scot C.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20

    Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.

    Published in:
    Canadian Urological Association Journal, 2014, v. 8, n. 11/12, p. 398, doi. 10.5489/cuaj.2426
    By:
    • Richter, Suzanne;
    • Jo-An Seah;
    • Pond, Gregory R.;
    • Gan, Hui K.;
    • Mackenzie, Mary J.;
    • Hotte, Sebastien J.;
    • Mukherjee, Som D.;
    • Murray, Nevin;
    • Kollmannsberger, Christian;
    • Heng, Daniel;
    • Haider, Masoom A.;
    • Halford, Robert;
    • Ivy, S. Percy;
    • Moore, Malcolm J.;
    • Sridhar, Srikala S.
    Publication type:
    Article
    21

    Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-021-02236-7
    By:
    • Voon, Pei Jye;
    • Chen, Eric X.;
    • Chen, Helen X.;
    • Lockhart, Albert C.;
    • Sahebjam, Solmaz;
    • Kelly, Karen;
    • Vaishampayan, Ulka N.;
    • Subbiah, Vivek;
    • Razak, Albiruni R.;
    • Renouf, Daniel J.;
    • Hotte, Sebastien J.;
    • Singh, Arti;
    • Bedard, Philippe L.;
    • Hansen, Aaron R.;
    • Ivy, S. Percy;
    • Wang, Lisa;
    • Stayner, Lee-Anne;
    • Siu, Lillian L.;
    • Spreafico, Anna
    Publication type:
    Article
    22
    23
    24
    25

    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.

    Published in:
    British Journal of Cancer, 2022, v. 126, n. 7, p. 1027, doi. 10.1038/s41416-021-01664-8
    By:
    • Konstantinopoulos, Panagiotis A.;
    • Cheng, Su-Chun;
    • Supko, Jeffrey G.;
    • Polak, Madeline;
    • Wahner-Hendrickson, Andrea E.;
    • Ivy, S. Percy;
    • Bowes, Brittany;
    • Sawyer, Hannah;
    • Basada, Patrice;
    • Hayes, Martin;
    • Curtis, Jennifer;
    • Horowitz, Neil;
    • Wright, Alexi A.;
    • Campos, Susana M.;
    • Ivanova, Elena V.;
    • Paweletz, Cloud P.;
    • Palakurthi, Sangeetha;
    • Liu, Joyce F.;
    • D'Andrea, Alan D.;
    • Gokhale, Prafulla C.
    Publication type:
    Article
    26

    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.

    Published in:
    2022
    By:
    • Konstantinopoulos, Panagiotis A;
    • Cheng, Su-Chun;
    • Supko, Jeffrey G;
    • Polak, Madeline;
    • Wahner-Hendrickson, Andrea E;
    • Ivy, S Percy;
    • Bowes, Brittany;
    • Sawyer, Hannah;
    • Basada, Patrice;
    • Hayes, Martin;
    • Curtis, Jennifer;
    • Horowitz, Neil;
    • Wright, Alexi A;
    • Campos, Susana M;
    • Ivanova, Elena V;
    • Paweletz, Cloud P;
    • Palakurthi, Sangeetha;
    • Liu, Joyce F;
    • D'Andrea, Alan D;
    • Gokhale, Prafulla C
    Publication type:
    journal article
    27
    28
    29
    30
    31
    32
    33

    CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer

    Published in:
    Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00123
    By:
    • Lee, Jung-Min;
    • Trepel, Jane B.;
    • Choyke, Peter;
    • Cao, Liang;
    • Sissung, Tristan;
    • Houston, Nicole;
    • Yu, Minshu;
    • Figg, William D.;
    • Turkbey, Ismail Baris;
    • Steinberg, Seth M.;
    • Min-Jung Lee;
    • Ivy, S. Percy;
    • Liu, Joyce F.;
    • Matulonis, Ursula A.;
    • Kohn, Elise C.;
    • Ford, James M.
    Publication type:
    Article
    34
    35

    A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).

    Published in:
    Breast Cancer Research & Treatment, 2023, v. 198, n. 3, p. 487, doi. 10.1007/s10549-023-06889-0
    By:
    • Malhotra, Monica K.;
    • Pahuja, Shalu;
    • Kiesel, Brian F.;
    • Appleman, Leonard J.;
    • Ding, Fei;
    • Lin, Yan;
    • Tawbi, Hussein A.;
    • Stoller, Ronald G.;
    • Lee, James J.;
    • Belani, Chandra P.;
    • Chen, Alice P.;
    • Giranda, Vincent L.;
    • Shepherd, Stacie Peacock;
    • Emens, Leisha A.;
    • Ivy, S. Percy;
    • Chu, Edward;
    • Beumer, Jan H.;
    • Puhalla, Shannon
    Publication type:
    Article
    36
    37
    38
    39

    Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors.

    Published in:
    JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 9, p. 596, doi. 10.1093/jnci/djq091
    By:
    • Maitland, Michael L.;
    • Bakris, George L.;
    • Black, Henry R.;
    • Chen, Helen X.;
    • Durand, Jean-Bernard;
    • Elliott, William J.;
    • Ivy, S. Percy;
    • Leier, Carl V.;
    • Lindenfeld, JoAnn;
    • Liu, Glenn;
    • Remick, Scot C.;
    • Steingart, Richard;
    • Tang, W. H. Wilson
    Publication type:
    Article
    40

    INCREASED PERFUSION DUE TO VASCULAR NORMALIZATION IMPROVES OXYGENATION AND SURVIVAL IN GLIOBLASTOMA PATIENTS TREATED WITH CEDIRANIB WITH OR WITHOUT CHEMORADIATION.

    Published in:
    Neuro-Oncology, 2014, v. 16, n. suppl_3, p. iii12, doi. 10.1093/neuonc/nou206.42
    By:
    • Batchelor, Tracy T.;
    • Gerstner, Elizabeth R.;
    • Emblem, Kyrre E.;
    • Duda, Dan G.;
    • Kalpathy-Cramer, Jayashree;
    • Snuderl, Matija;
    • Ancukiewicz, Marek;
    • Polaskova, Pavlina;
    • Pinho, Marco C.;
    • Jennings, Dominique;
    • Plotkin, Scott R.;
    • Chi, Andrew S.;
    • Eichler, April F.;
    • Dietrich, Jorg;
    • Hochberg, Fred H.;
    • Lu-Emerson, Christine;
    • Iafrate, A. John;
    • Ivy, S. Percy;
    • Rosen, Bruce;
    • Loeffler, Jay S.
    Publication type:
    Article
    41